HawkScreener
Register Sign In
Dashboard Screener Heatmap Compare Sign In

AZTA

Azenta, Inc. (NASDAQ)

Healthcare — Medical Instruments & Supplies

Azenta, Inc. provides biological and chemical compound sample exploration and management solutions for the life sciences industry in the United States, China, the United Kingdom, rest of Europe, the Asia Pacific, and internationally. It operates through Sample Management Solutions and Multiomics segments. The Sample Management Solutions segment provides sample management products and services, including automated stores, cryogenic systems, automated sample tubes, consumables and instruments, and controlled rate thawing devices, as well as sample repository services. This segment also offers consultation services to clients throughout their experimental design and implementation processes. The Multiomics segment provides genomic and other sample analysis services comprising gene sequencing, gene synthesis, and related services. The company has a strategic partnership with Frontier Space Ltd to conduct scientific experiments in space. The company was formerly known as Brooks Automation, Inc. and changed its name to Azenta, Inc. in December 2021. Azenta, Inc. was founded in 1978 and is headquartered in Burlington, Massachusetts.

None 5 analysts
$26.19
+$0.67 (+2.63%)
Target: $26.20 (0.0%)
Sign in to add AZTA to a watchlist or set price alerts.

Price History

52-Week Range

Fundamentals

Market Cap$1.21B
P/E Ratio (TTM)-
Forward P/E42.65
EPS (TTM)$-2.41
Dividend Yield-
Profit Margin-29.06%
Revenue Growth1.00%
ROE-6.81%
Debt/Equity3.58
Recommendation None
Analyst Target$26.20
Analysts5
Indexes NASDAQ

Technical Indicators

RSI (14)77.5
Beta1.40
SMA 20-
SMA 40-
52-Week High$41.73
52-Week Low$15.93
50-Day Avg$22.24
200-Day Avg$28.44
Avg Volume$1.12M
Volume630.0K

Performance Analysis

NEUTRAL

AZTA presents a mixed picture with both positive and negative indicators.

~ Trading at 40% of its 52-week range.
- RSI at 77.5 indicates overbought conditions — a pullback may be due.
~ Modest revenue growth of 1.0% year-over-year.
- Operating at a loss with -29.1% margin.
~ Wall Street consensus is "none" from 5 analysts.
+ Average analyst target of $26.20 implies 0.0% upside.

Recent News

Loading news...
Sign in for full analysis Unlock insider trading data, options chain, news feed, and more.
Sign In

Last updated: Jul 02, 2026 12:58 UTC

Back to Screener Export Report